AZD1283Potent P2Y12 antagonist CAS# 919351-41-0 |
- Ro 31-8220 Mesylate
Catalog No.:BCC4999
CAS No.:138489-18-6
- CHIR-99021 (CT99021)
Catalog No.:BCC1275
CAS No.:252917-06-9
- CHIR-98014
Catalog No.:BCC3751
CAS No.:252935-94-7
- TWS119
Catalog No.:BCC4512
CAS No.:601514-19-6
- GSK-3 inhibitor 1
Catalog No.:BCC4126
CAS No.:603272-51-1
- GSK-3 Inhibitor IX (BIO)
Catalog No.:BCC4510
CAS No.:667463-62-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 919351-41-0 | SDF | Download SDF |
| PubChem ID | 23649325 | Appearance | Powder |
| Formula | C23H26N4O5S | M.Wt | 470.54 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 100 mg/mL (212.52 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | ethyl 6-[4-(benzylsulfonylcarbamoyl)piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate | ||
| SMILES | CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=CC=CC=C3)C | ||
| Standard InChIKey | NEMHKCNXXRQYRF-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C23H26N4O5S/c1-3-32-23(29)20-13-19(14-24)21(25-16(20)2)27-11-9-18(10-12-27)22(28)26-33(30,31)15-17-7-5-4-6-8-17/h4-8,13,18H,3,9-12,15H2,1-2H3,(H,26,28) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | High affinity P2Y12 antagonist (Kd = 11 nM). Causes a dose-dependent increase in blood flow and inhibits ADP-induced platelet aggregation in vivo. Antithrombotic. |
AZD1283 Dilution Calculator
AZD1283 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1252 mL | 10.6261 mL | 21.2522 mL | 42.5044 mL | 53.1304 mL |
| 5 mM | 0.425 mL | 2.1252 mL | 4.2504 mL | 8.5009 mL | 10.6261 mL |
| 10 mM | 0.2125 mL | 1.0626 mL | 2.1252 mL | 4.2504 mL | 5.313 mL |
| 50 mM | 0.0425 mL | 0.2125 mL | 0.425 mL | 0.8501 mL | 1.0626 mL |
| 100 mM | 0.0213 mL | 0.1063 mL | 0.2125 mL | 0.425 mL | 0.5313 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: 0.011, 0.025 and 3.2 μM for binding, GTPγS and residual platelet count (RPC), respectively
The central role of the P2Y12 receptor in platelet function makes it an attractive target for the development of novel antiplatelet therapies. AZD1283 is found to be a potent, selective and reversible antagonist of the P2Y12 receptor.
In vitro: It was observed that the benzylic AZD1283 and its analogue 13 were both potent in the higher order residual platelet count assay in which the two tested 5-chlorothienyls showed low (IC50 >22 μM) potency [1].
In vivo: In a modified Folts model in dog, both AZD1283 and its analogue 13 could dose-dependently induce increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10.0 μg/kg/min, respectively. The dose that induced a larger than 3-fold increase in bleeding time were 33 and 100 μg/kg/min for AZD1283 and 13, respectively [2].
Clinical trials: Currenlty there is no clinical data available.
Reference:
[1] Bach P, Antonsson T, Bylund R, Björkman JA, Österlund K, Giordanetto F, van Giezen JJ, Andersen SM, Zachrisson H, Zetterberg F. Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283. J Med Chem. 2013;56(17):7015-24.
- Rubrisandrin A
Catalog No.:BCN3248
CAS No.:919289-30-8
- Ro 15-4513
Catalog No.:BCC7230
CAS No.:91917-65-6
- Atrial natriuretic factor (1-28) (human, porcine)
Catalog No.:BCC5839
CAS No.:91917-63-4
- 1-Methoxyindole-3-carboxylic acid
Catalog No.:BCN3946
CAS No.:91913-76-7
- 19-[(beta-D-glucopyranosyl)oxy]-19-oxo-ent-labda-8(17),13-dien-16,15-olide
Catalog No.:BCN1308
CAS No.:919120-78-8
- GPi 688
Catalog No.:BCC6091
CAS No.:918902-32-6
- TH-302
Catalog No.:BCC1998
CAS No.:918633-87-1
- PLX-4720
Catalog No.:BCC1280
CAS No.:918505-84-7
- BRAF inhibitor
Catalog No.:BCC1436
CAS No.:918505-61-0
- Vemurafenib (PLX4032, RG7204)
Catalog No.:BCC1269
CAS No.:918504-65-1
- 5,7,4'-Trimethoxyafzelechin
Catalog No.:BCN7933
CAS No.:918428-88-3
- Cefdinir
Catalog No.:BCC3747
CAS No.:91832-40-5
- Zatebradine hydrochloride
Catalog No.:BCC7286
CAS No.:91940-87-3
- Buergerinin B
Catalog No.:BCN4555
CAS No.:919769-83-8
- Saikosaponin H
Catalog No.:BCN7808
CAS No.:91990-63-5
- OF-1
Catalog No.:BCC5579
CAS No.:919973-83-4
- o-Acetoacetaniside
Catalog No.:BCC9107
CAS No.:92-15-9
- 6-Methylcoumarin
Catalog No.:BCN6906
CAS No.:92-48-8
- Scopoletin
Catalog No.:BCN4470
CAS No.:92-61-5
- Phenothiazine
Catalog No.:BCC4701
CAS No.:92-84-2
- 4,4'-Biphenol
Catalog No.:BCC8654
CAS No.:92-88-6
- 4-Acetylbiphenyl
Catalog No.:BCC8673
CAS No.:92-91-1
- 4-Biphenylcarboxylic acid
Catalog No.:BCC8701
CAS No.:92-92-2
- Influenza Hemagglutinin (HA) Peptide
Catalog No.:BCC2563
CAS No.:92000-76-5
Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.[Pubmed:23899349]
J Med Chem. 2013 Sep 12;56(17):7015-24.
Synthesis and structure-activity relationships of ethyl 6-aminonicotinate acyl sulfonamides, which are potent antagonists of the P2Y12 receptor, are presented. Shifting from 5-chlorothienyl to benzyl sulfonamides significantly increased the potency in the residual platelet count assay. Evaluation of PK parameters in vivo in dog for six compounds showed a 10-fold higher clearance for the azetidines than for the matched-pair piperidines. In a modified Folts model in dog, both piperidine 3 and azetidine 13 dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 mug/kg/min, respectively. The doses that induced a larger than 3-fold increase in bleeding time were 33 and 100 mug/kg/min for 3 and 13, respectively. Thus, the therapeutic index (TI) was >/= 10 for both compounds. On the basis of these data, compound 3 was progressed into human clinical trials as candidate drug AZD1283.
